Sigyn Therapeutics Appoints Medical Technology Expert to Advance Dialysis-Like Cardiovascular Treatments

Sigyn Therapeutics, Inc. has appointed Dr. Christoph Zaba to its Scientific Advisory Board, bringing extensive experience in medical technology and extracorporeal therapies to advance the company's dialysis-like treatments for cardiovascular disease. Dr. Zaba previously directed global product management in therapeutic apheresis at Fresenius Medical Care, focusing on immunoadsorption therapies for autoimmune diseases and lipoprotein apheresis for removing pathogenic lipoproteins from blood. Lipoprotein apheresis is an established extracorporeal methodology that reduces lipoprotein(a) and low-density lipoprotein cholesterol in the bloodstream, with studies showing 55% to 98% reductions in major adverse cardiovascular events. While therapeutic benefits are well-documented, treatment access remains limited to fewer than 60 specialized apheresis centers in the United States.

Sigyn Therapy™ represents a potential breakthrough as a whole blood adsorption technology designed for use on existing dialysis machines located in approximately 7,500 U.S. dialysis clinics. The technology aims to reduce both Lp(a) and LDL-C while simultaneously targeting inflammatory molecules that fuel cardiovascular disease progression. More information about the company's scientific advisory board can be found at https://www.sigyntherapeutics.com/about/scientific-advisory-board. The company recently disclosed plans to commence a multi-site clinical feasibility study of Sigyn Therapy™ in high-risk cardiovascular disease subjects with end-stage renal disease. Successful completion of this study could lead to a pivotal efficacy study necessary for potential market clearance to treat cardiovascular disease, which remains the leading cause of global deaths.

Beyond cardiovascular applications, Sigyn Therapeutics is developing complementary dialysis-like cancer therapies including ImmunePrep™ for immunotherapeutic antibody delivery optimization, ChemoPrep™ for enhanced chemotherapy targeting, and ChemoPure™ for reducing chemotherapy toxicity. The company intends to advance these cancer treatment candidates through joint venture development relationships. Additional information about the company's broader initiatives is available at https://www.sigyntherapeutics.com. The appointment of Dr. Zaba signals a strategic move to leverage his expertise in extracorporeal therapies at a critical juncture for the company's development pipeline. His background in therapeutic apheresis directly aligns with Sigyn's approach to blood purification technologies, potentially accelerating the translation of these treatments from concept to clinical practice.

The significance of this development lies in addressing a major healthcare gap. Current lipoprotein apheresis treatments, while effective, suffer from severe accessibility limitations due to their confinement to specialized centers. By adapting technology for existing dialysis infrastructure, Sigyn Therapy™ could democratize access to these cardiovascular interventions, potentially reaching millions of patients who currently lack treatment options. This expansion of treatment availability could have profound public health implications given cardiovascular disease's status as the world's leading cause of mortality. The company's parallel development of cancer therapies suggests a broader vision for dialysis-like technologies beyond cardiovascular applications, potentially creating new treatment paradigms across multiple disease areas.